The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous Names X None

**Entity Type** 

Limited Partnership

General Partnership

**Business Trust** 

Other (Specify)

Limited Liability Company

X Corporation

0001274792

Name of Issuer
MERRIMACK PHARMACEUTICALS

Name of Issuer

INC

Jurisdiction of Incorporation/Organization

**DELAWARE** 

Year of Incorporation/Organization

Over Five Years Ago

X Within Last Five Years (Specify Year) 2010

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

MERRIMACK PHARMACEUTICALS INC

Street Address 1 Street Address 2

ONE KENDALL SQUARE SUITE B7201

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

CAMBRIDGE MASSACHUSETTS 02139 617-441-1000

3. Related Persons

Last Name First Name Middle Name

**Street Address 2** 

Mulroy Robert J.

One Kendall Square Suite B7201

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

**Relationship:** X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

**Street Address 1** 

Last Name First Name Middle Name

Sullivan William A.

Street Address 1 Street Address 2

One Kendall Square Suite B7201

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

**Relationship:** X Executive Officer Director Promoter

Clarification of Response (if Necessary):

**Last Name First Name** Middle Name Crocker Gary **Street Address 1 Street Address 2** Suite B7201 One Kendall Square State/Province/Country ZIP/PostalCode Cambridge **MASSACHUSETTS** 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name Dresser **James Street Address 1 Street Address 2** One Kendall Square Suite B7201 City State/Province/Country ZIP/PostalCode Cambridge **MASSACHUSETTS** 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name Middle Name** Fehr Gordon **Street Address 1 Street Address 2** Suite B7201 One Kendall Square City State/Province/Country ZIP/PostalCode Cambridge **MASSACHUSETTS** 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name Gay Robert **Street Address 2 Street Address 1** Suite B7201 One Kendall Square ZIP/PostalCode City **State/Province/Country MASSACHUSETTS** Cambridge 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name Lovenberg Walter **Street Address 1 Street Address 2** One Kendall Square Suite B7201 City State/Province/Country ZIP/PostalCode Cambridge **MASSACHUSETTS** 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name

Nash Sarah

Street Address 1 Street Address 2

One Kendall Square Suite B7201

City State/Province/Country ZIP/PostalCode

Cambridge **MASSACHUSETTS** 02139

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

**Middle Name Last Name** First Name

Porter

Michael

**Street Address 1 Street Address 2** 

One Kendall Square

Suite B7201

State/Province/Country

ZIP/PostalCode

Cambridge

**MASSACHUSETTS** 

02139

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

**Last Name First Name** Middle Name

Sinskey

Anthony

**Street Address 1** 

**Street Address 2** 

One Kendall Square

Suite B7201

City

**State/Province/Country** ZIP/PostalCode

02139

Cambridge **MASSACHUSETTS** 

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing

Banking & Financial Services Biotechnology Restaurants Commercial Banking Health Insurance Technology

Insurance Hospitals & Physicians Computers Investing

X Pharmaceuticals Telecommunications **Investment Banking** 

Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel an investment company under Real Estate

Airlines & Airports the Investment Company Commercial

Act of 1940? **Lodging & Conventions** Construction Yes No Tourism & Travel Services

Other Banking & Financial Services **REITS & Finance** Other Travel

**Business Services** Residential

Other Energy Other Real Estate

Coal Mining

Oil & Gas

Other Energy

**Electric Utilities** 

**Energy Conservation Environmental Services** 

5. Issuer Size

OR **Revenue Range Aggregate Net Asset Value Range** 

No Revenues No Aggregate Net Asset Value

\$1 - \$5,000,000 \$1 - \$1,000,000

\$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,000 \$25,000,001 - \$50,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000

Over \$100,000,000

X Decline to Disclose
Not Applicable

Over \$100,000,000

Decline to Disclose
Not Applicable

# 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Rule 505

Rule 504 (b)(1)(i)

X Rule 506

Rule 504 (b)(1)(ii) Securities Act Section 4(5)

Investment Company Act Section 3(c)

 Section 3(c)(1)
 Section 3(c)(9)

 Section 3(c)(2)
 Section 3(c)(10)

 Section 3(c)(3)
 Section 3(c)(11)

 Section 3(c)(4)
 Section 3(c)(12)

 Section 3(c)(5)
 Section 3(c)(13)

 Section 3(c)(6)
 Section 3(c)(14)

Section 3(c)(7)

#### 7. Type of Filing

X New Notice Date of First Sale 2011-04-06 First Sale Yet to Occur Amendment

8. Duration of Offering

Rule 504 (b)(1)(iii)

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity
Debt
Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or

Other (describe)

### 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

### 12. Sales Compensation

Recipient CRD Number X None

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None

Street Address 1 Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply) All States Foreign/non-US

Check "All States" or check individual States

### 13. Offering and Sales Amounts

Total Offering Amount \$77,000,000 USD or Indefinite

Total Amount Sold \$77,000,000 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

#### 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

61		

## 15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

#### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
MERRIMACK PHARMACEUTICALS INC	/s/ William A. Sullivan	William A. Sullivan	Vice President of Finance	2011-04-11

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.